1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
697F5D484A00328BF652582B10035EBBB
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-gaining-support-patient-adherence-programs-structure-resources-vendor-management?opendocument
18
19opendocument
2044.220.247.152
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Patient Focused Services » Patient Support Programs

Gaining Support for Patient Adherence Programs: Structure, Resources and Vendor Management

ID: 5514


Features:

3 Info Graphics

17 Data Graphics

220+ Metrics

4 Narratives


Pages/Slides: 28


Published: Pre-2019


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Gaining Support for Patient Adherence Programs: Structure, Resources and Vendor Management”


STUDY OVERVIEW


Pharmaceutical and biotechnology companies seek to improve their patient adherence programs to drive better outcomes and reduce costs. To have a significant impact on patient adherence, it is critical to optimize the structure and resources of adherence programs.

However, gaining adequate support and resources for adherence programs and choosing the right vendors for strategic aspects of the program are some of the persistent internal challenges for many companies.

Best Practices, LLC undertook this benchmarking study to probe how leading pharmaceutical and biotechnology companies develop and manage their patient adherence programs. In particular, this study delivers adherence program benchmarks around structure, leadership, investment, staffing and vendor management.


KEY TOPICS

  • Examining Current and Future Staffing and Investment Trends
  • Structure, Process & Vendor Management: Examining Where Adherence Groups Report and Program Management Trends
  • Leadership: Activities and Channels

KEY METRICS

  • What is your organization’s total Full-Time Equivalent (FTE) staffing investment dedicated to adherence program design and management?
  • What is your organization’s approximate total investment into adherence program design and management?
  • At which new product development stage does the adherence group’s role begin? Ideally, at which new product development stage should the adherence group’s role begin?
  • Where does the staff tasked with adherence program design and management report?
  • Where does the budget reside for adherence design and management activities?
  • Which agency/vendor partners have you had the best experiences with in regards to the strategy, design, implementation and management for your adherence programs?

SAMPLE KEY FINDINGS

  • Staffing - Contractors and Consultants: On average, companies utilized four contracted FTEs for every in-house FTE, not including call centers.
  • Structure - Budget Allocation: Most large biopharma reported that they allocate budget for programs on a per product basis, while some small-medium biopharma take into account revenue of products.

METHODOLOGY


Best Practices, LLC engaged 20 leaders with extensive experience in managing patient adherence operations at 16 leading biopharmaceutical companies.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care; Clinical Research; Laboratories


Companies Profiled:
Abbvie; Alkermes; Amgen; Bayer; Biogen; Celgene; Eisai; Genentech; Janssen; Jazz Pharmaceuticals; LEO Pharma; OTSUKA; Sanofi; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.